Literature DB >> 20473312

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.

Maria Kleppe1, Idoya Lahortiga, Tiama El Chaar, Kim De Keersmaecker, Nicole Mentens, Carlos Graux, Katrien Van Roosbroeck, Adolfo A Ferrando, Anton W Langerak, Jules P P Meijerink, François Sigaux, Torsten Haferlach, Iwona Wlodarska, Peter Vandenberghe, Jean Soulier, Jan Cools.   

Abstract

PTPN2 (protein tyrosine phosphatase non-receptor type 2, also known as TC-PTP) is a cytosolic tyrosine phosphatase that functions as a negative regulator of a variety of tyrosine kinases and other signaling proteins. In agreement with its role in the regulation of the immune system, PTPN2 was identified as a susceptibility locus for autoimmune diseases. In this work, we describe the identification of focal deletions of PTPN2 in human T-cell acute lymphoblastic leukemia (T-ALL). Deletion of PTPN2 was specifically found in T-ALLs with aberrant expression of the TLX1 transcription factor oncogene, including four cases also expressing the NUP214-ABL1 tyrosine kinase. Knockdown of PTPN2 increased the proliferation and cytokine sensitivity of T-ALL cells. In addition, PTPN2 was identified as a negative regulator of NUP214-ABL1 kinase activity. Our study provides genetic and functional evidence for a tumor suppressor role of PTPN2 and suggests that expression of PTPN2 may modulate response to treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473312      PMCID: PMC2957655          DOI: 10.1038/ng.587

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  30 in total

1.  Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

Authors:  Kim De Keersmaecker; Carlos Graux; Maria D Odero; Nicole Mentens; Riet Somers; Johan Maertens; Iwona Wlodarska; Peter Vandenberghe; Anne Hagemeijer; Peter Marynen; Jan Cools
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

2.  HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL).

Authors:  Jean Soulier; Emmanuelle Clappier; Jean-Michel Cayuela; Armelle Regnault; Marina García-Peydró; Hervé Dombret; André Baruchel; Maria-Luisa Toribio; François Sigaux
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

3.  Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases.

Authors:  A J Flint; T Tiganis; D Barford; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

4.  Substrate-trapping techniques in the identification of cellular PTP targets.

Authors:  C Blanchetot; M Chagnon; N Dubé; M Hallé; M L Tremblay
Journal:  Methods       Date:  2005-01       Impact factor: 3.608

5.  Association of the T-cell protein tyrosine phosphatase with nuclear import factor p97.

Authors:  T Tiganis; A J Flint; S A Adam; N K Tonks
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

6.  Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase.

Authors:  Catherine van Vliet; Patricia E Bukczynska; Michelle A Puryer; Christine M Sadek; Benjamin J Shields; Michel L Tremblay; Tony Tiganis
Journal:  Nat Immunol       Date:  2005-02-06       Impact factor: 25.606

7.  Cloning and characterization of a mouse cDNA encoding a cytoplasmic protein-tyrosine-phosphatase.

Authors:  B Mosinger; U Tillmann; H Westphal; M L Tremblay
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

8.  Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia.

Authors:  D D Wright; B M Sefton; M P Kamps
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

9.  New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling.

Authors:  Willem A Dik; Karin Pike-Overzet; Floor Weerkamp; Dick de Ridder; Edwin F E de Haas; Miranda R M Baert; Peter van der Spek; Esther E L Koster; Marcel J T Reinders; Jacques J M van Dongen; Anton W Langerak; Frank J T Staal
Journal:  J Exp Med       Date:  2005-05-31       Impact factor: 14.307

10.  COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus.

Authors:  J A Lorenzen; C Y Dadabay; E H Fischer
Journal:  J Cell Biol       Date:  1995-11       Impact factor: 10.539

View more
  81 in total

1.  Genome-wide association analysis of Sasang constitution in the Korean population.

Authors:  Bu-Yeo Kim; Hee-Jeong Jin; Jong Yeol Kim
Journal:  J Altern Complement Med       Date:  2012-03-06       Impact factor: 2.579

2.  Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Jan Cools
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

3.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

4.  Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Authors:  Sandrine Degryse; Simon Bornschein; Charles E de Bock; Emilie Leroy; Marlies Vanden Bempt; Sofie Demeyer; Kris Jacobs; Ellen Geerdens; Olga Gielen; Jean Soulier; Christine J Harrison; Stefan N Constantinescu; Jan Cools
Journal:  Blood       Date:  2017-11-29       Impact factor: 22.113

5.  Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.

Authors:  Qian Wang; Huiying Qiu; Hui Jiang; Lili Wu; Shasha Dong; Jinlan Pan; Wenjuan Wang; Nana Ping; Jing Xia; Aining Sun; Depei Wu; Yongquan Xue; Hans G Drexler; Roderick A F Macleod; Suning Chen
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

6.  Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma.

Authors:  Maria Kleppe; Thomas Tousseyn; Eva Geissinger; Zeynep Kalender Atak; Stein Aerts; Andreas Rosenwald; Iwona Wlodarska; Jan Cools
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

Review 7.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Authors:  Thomas A Waldmann; Jing Chen
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

8.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Authors:  Robert T Manguso; Hans W Pope; Margaret D Zimmer; Flavian D Brown; Kathleen B Yates; Brian C Miller; Natalie B Collins; Kevin Bi; Martin W LaFleur; Vikram R Juneja; Sarah A Weiss; Jennifer Lo; David E Fisher; Diana Miao; Eliezer Van Allen; David E Root; Arlene H Sharpe; John G Doench; W Nicholas Haining
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

Review 9.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

10.  Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic.

Authors:  Charles G Mullighan; Cheryl L Willman
Journal:  J Adolesc Young Adult Oncol       Date:  2011-06       Impact factor: 2.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.